The necessity and risk factors of subsequent fusion after decompression alone for lumbar spinal stenosis with lumbar spondylolisthesis: 5 years follow-up in two different large populations.


Journal

The spine journal : official journal of the North American Spine Society
ISSN: 1878-1632
Titre abrégé: Spine J
Pays: United States
ID NLM: 101130732

Informations de publication

Date de publication:
10 2020
Historique:
received: 10 02 2020
revised: 25 04 2020
accepted: 28 04 2020
pubmed: 18 5 2020
medline: 25 6 2021
entrez: 18 5 2020
Statut: ppublish

Résumé

Although decompression without fusion is a reasonable surgical treatment option for some patients with lumbar spinal stenosis (LSS) secondary to spondylolisthesis, some of these patients will require secondary surgery for subsequent fusion. Long-term outcome and need for subsequent fusion in patients treated with decompression alone in the setting of lumbar spondylolisthesis remains controversial. The aim of this study was to examine the rate, timing, and risk factors of subsequent fusion for patients after decompression alone for LSS with spondylolisthesis. A retrospective cohort study. Patients who had LSS with spondylolisthesis and underwent decompression alone at 1 or 2 levels as a primary lumbar surgery with more than 5 year follow-up. The rate, timing, and risk factors for subsequent fusion. Subjects were extracted from both public and private insurance resources in a nationwide insurer database. Risk factors for subsequent fusion were evaluated by multivariate cox proportion-hazard regression controlling for age, gender, comorbidities and the presence or absence of claudication. Five thousand eight hundred and seventy-five patients in the public insurance population (PI population) and 1,456 patients in the private insurance population (PrI population) were included in this study. The rates of patients who needed subsequent fusion were 1.9% at 1 year, 3.5% at 2 years, and 6.7% at 5 years in the PI population, whereas they were 4.3% at 1 year, 8.9% at 2 years, 14.6% at 5 years in the PrI population. The time to subsequent fusion was 730 (365-1234) days in the PI population and 588 (300-998) days in the PrI population. Age less than 70 years, presence of neurogenic claudication and rheumatoid arthritis (RA)/collagen vascular diseases (CVD) were independent risk factors for subsequent fusion in both populations. Decompression surgery alone can demonstrate good outcomes in some patients with LSS with spondylolisthesis. It is important for surgeons to recognize, however, that patient age less than 70 years, symptomatic neurogenic claudication, and presence of RA and/or CVD are significant independent factors associated with greater likelihood of needing secondary fusion surgery.

Sections du résumé

BACKGROUND/CONTEXT
Although decompression without fusion is a reasonable surgical treatment option for some patients with lumbar spinal stenosis (LSS) secondary to spondylolisthesis, some of these patients will require secondary surgery for subsequent fusion. Long-term outcome and need for subsequent fusion in patients treated with decompression alone in the setting of lumbar spondylolisthesis remains controversial.
PURPOSE
The aim of this study was to examine the rate, timing, and risk factors of subsequent fusion for patients after decompression alone for LSS with spondylolisthesis.
STUDY DESIGN/SETTING
A retrospective cohort study.
PATIENT SAMPLE
Patients who had LSS with spondylolisthesis and underwent decompression alone at 1 or 2 levels as a primary lumbar surgery with more than 5 year follow-up.
OUTCOME MEASURES
The rate, timing, and risk factors for subsequent fusion.
METHODS
Subjects were extracted from both public and private insurance resources in a nationwide insurer database. Risk factors for subsequent fusion were evaluated by multivariate cox proportion-hazard regression controlling for age, gender, comorbidities and the presence or absence of claudication.
RESULTS
Five thousand eight hundred and seventy-five patients in the public insurance population (PI population) and 1,456 patients in the private insurance population (PrI population) were included in this study. The rates of patients who needed subsequent fusion were 1.9% at 1 year, 3.5% at 2 years, and 6.7% at 5 years in the PI population, whereas they were 4.3% at 1 year, 8.9% at 2 years, 14.6% at 5 years in the PrI population. The time to subsequent fusion was 730 (365-1234) days in the PI population and 588 (300-998) days in the PrI population. Age less than 70 years, presence of neurogenic claudication and rheumatoid arthritis (RA)/collagen vascular diseases (CVD) were independent risk factors for subsequent fusion in both populations.
CONCLUSIONS
Decompression surgery alone can demonstrate good outcomes in some patients with LSS with spondylolisthesis. It is important for surgeons to recognize, however, that patient age less than 70 years, symptomatic neurogenic claudication, and presence of RA and/or CVD are significant independent factors associated with greater likelihood of needing secondary fusion surgery.

Identifiants

pubmed: 32417500
pii: S1529-9430(20)30176-5
doi: 10.1016/j.spinee.2020.04.026
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1566-1572

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Hikari Urakawa (H)

Hospital for Special Surgery, 535 E. 70th St, New York, NY 10021, USA.

Tuckerman Jones (T)

Hospital for Special Surgery, 535 E. 70th St, New York, NY 10021, USA.

Andre Samuel (A)

Hospital for Special Surgery, 535 E. 70th St, New York, NY 10021, USA.

Avani S Vaishnav (AS)

Hospital for Special Surgery, 535 E. 70th St, New York, NY 10021, USA.

Yahya Othman (Y)

Hospital for Special Surgery, 535 E. 70th St, New York, NY 10021, USA.

Sohrab Virk (S)

Hospital for Special Surgery, 535 E. 70th St, New York, NY 10021, USA.

Yoshihiro Katsuura (Y)

Hospital for Special Surgery, 535 E. 70th St, New York, NY 10021, USA; Weill Cornell Medical College, New York, NY, USA.

Sravisht Iyer (S)

Hospital for Special Surgery, 535 E. 70th St, New York, NY 10021, USA; Weill Cornell Medical College, New York, NY, USA.

Steven McAnany (S)

Hospital for Special Surgery, 535 E. 70th St, New York, NY 10021, USA; Weill Cornell Medical College, New York, NY, USA.

Todd Albert (T)

Hospital for Special Surgery, 535 E. 70th St, New York, NY 10021, USA; Weill Cornell Medical College, New York, NY, USA.

Catherine Himo Gang (CH)

Hospital for Special Surgery, 535 E. 70th St, New York, NY 10021, USA.

Sheeraz A Qureshi (SA)

Hospital for Special Surgery, 535 E. 70th St, New York, NY 10021, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: sheerazqureshimd@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH